Moonshots with Peter Diamandis

Investors seeking high-conviction exposure to Longevity & Regenerative Biotechnology should focus on United Therapeutics Corporation (UTHR) as it leads the synthetic organ and xenotransplantation market. Key near-term catalysts for UTHR include launching commercial xenokidney manufacturing facilities in late 2024, enrolling patients for its 50-person XenoHeart clinical trial, and initiating iViva autologous organ trials by 2028. Monitor private electric aviation firm Beta Technologies for a future public listing, as its zero-emission aircraft solve the critical 12-hour transport window required for distributed organs. Keep private startup GC Technologies on your watchlist for potential IPO or acquisition opportunities due to its breakthrough platform that cuts stem cell production times from three months to just two weeks. Long-term capital should remain positioned across the broader Regenerative Medicine sector, which is projected to reach major commercial inflection points and longevity milestones throughout the 2030s.

Consider building positions in Advanced Micro Devices (AMD) and specialized photonics hardware developers as data centers look to diversify away from NVIDIA (NVDA) over the next 18 to 24 months.

Investors should allocate capital toward regional natural gas infrastructure and data center cooling suppliers to profit from the critical power bottlenecks constraining artificial intelligence expansion.

Prepare for immediate commercial opportunities in preventive healthcare over the next 6 to 9 months as longevity platform Fountain Life launches its global AI diagnostic franchising model.

Traditional enterprises holding decades of unique operational records can generate immediate liquidity by packaging and licensing proprietary datasets to labs like OpenAI and Scale AI for $5 million to $15 million per deal.

Monitor venture rounds and public health-tech equities in the Brain-Computer Interface (BCI) space as medical approval pathways pave the way for broad commercial cognitive enhancement over the next 5 years.

Maintain long exposure to NVIDIA (NVDA) and AI Compute Infrastructure providers, as structural hardware shortages continue to push H100 rental rates up 22% alongside multi-year cloud backlogs.

Monitor private markets and upcoming public offering filings for Anthropic (Pre-IPO), which is targeting a potential $2 trillion valuation supported by a rapid $26 billion revenue run-rate.

Buy Alphabet (GOOGL) to capitalize on its expanding enterprise healthcare moat following the release of the Alpha Genome Atlas.

Allocate toward AI-Driven Drug Discovery leaders like Insilico Medicine as its AI-designed drug Rentoceratib reaches Phase 3 clinical trials, while favoring data-rich pharmaceutical incumbents like Moderna (MRNA) that are commercializing proprietary data moats.

Exercise caution with High Bandwidth Memory (HBM) suppliers such as SK Hynix, as cost-efficient model architectures like DeepSeek could reduce long-term memory hardware intensity.

Buy and hold NVIDIA (NVDA) as the primary AI infrastructure leader, supported by massive, ongoing demand for its Blackwell chips to power large-scale model training clusters.

Invest in Tesla (TSLA) to capture high-margin recurring software revenue from its decentralized CyberCab autonomous fleet network and vertically integrated Optimus humanoid robotics.

Allocate capital to AI Data Center Infrastructure providers—specifically targeting liquid cooling, HVAC systems, and electrical equipment suppliers—to profit from the immediate bottlenecks in global data center expansion.

Build positions in Moderna (MRNA) as the company leverages generative AI to significantly compress timelines and reduce costs in mRNA therapeutic development.

Gain long-term exposure to Humanoid Robotics and Preventative Healthtech platforms positioned to solve mounting global labor deficits as the population over 65 expands rapidly.

Consider investing in Tesla (TSLA) as it prepares to deploy an initial fleet of 5,000 autonomous Cybercab vehicles in Nevada over the next 12 months at an industry-leading $30,000 target price point.

Maintain a core position in NVIDIA (NVDA) to benefit from durable semiconductor pricing power driven by frontier artificial intelligence training runs scaling up to $1 billion each.

Buy GLP-1 therapeutic leaders Novo Nordisk (NVO) and Eli Lilly (LLY) to capture long-term upside as clinical studies expand their market beyond weight loss into longevity and multi-organ disease prevention.

Allocate capital toward nuclear energy infrastructure and Small Modular Reactors (SMRs) to capture surging data center electricity demand ahead of commercial rollouts projected within 3 to 4 years.

Target application-layer software leaders like Salesforce (CRM) that are actively integrating frontier AI models into proprietary business workflows to drive new revenue streams.

Investors should prioritize the Data Center Infrastructure and Energy sector by targeting suppliers of electrical transformers, thermal cooling systems, and independent power generation to capitalize on a projected 15-gigawatt grid deficit by 2027.

Tesla (TSLA) presents a high-conviction energy infrastructure play as it scales proprietary solar production to 100 gigawatts annually to meet surging data center power demands.

Maintain a closely monitored position in NVIDIA (NVDA), balancing its near-term hardware dominance against long-term moat erosion from emerging AI-automated ASIC design platforms like Architect Labs.

Gain exposure to enterprise software providers pivoting to high-margin, outcome-based pricing models that monetize labor replacement, particularly via ecosystems like Amazon Web Services (AMZN) and Salesforce (CRM).

In private markets, seek secondary share exposure to SpaceX as its rapid expansion into natural gas turbines, orbital compute, and developer platforms fuels substantial pre-IPO valuation growth.

Investors should look to Broadcom (AVGO) as leading AI labs adopt custom application-specific chips like the Jalapeno processor to significantly lower computing and energy costs. While NVIDIA (NVDA) maintains dominant market share with strong forward quarterly revenue guidance of $108 billion, investors should closely monitor its profit margins as custom silicon alternatives enter the market. Tesla (TSLA) offers high-margin growth potential as it scales its autonomous Cybercab / Robotaxi network, targeting 2,500 commercial vehicles in Las Vegas over the coming year. Allocate capital to the Nuclear Energy and Small Modular Reactor (SMR) theme, particularly HALEU uranium enrichment suppliers, to profit from the surging power demand of AI data centers ahead of 2030. Finally, Apple (AAPL) provides an attractive edge-computing play as its Mac Studio M5 Ultra enables privacy-sensitive enterprises like healthcare and legal firms to run frontier AI models locally instead of paying expensive cloud subscription fees.

Investors should consider Alphabet Inc. (GOOGL) as its Waymo autonomous driving unit dramatically accelerates its timeline to commercial robotaxi profitability by slashing vehicle hardware costs from $115,000 down to $20,000.

Maintain a high-conviction position in NVIDIA Corporation (NVDA) as the company commits $6 billion to open-source software and talent acquisitions, cementing a strong moat to ensure sustained long-term demand for its GPUs.

Reduce exposure or take a defensive stance against legacy in-flight connectivity providers Viasat (VSAT) and Gogo (GOGO), which are facing severe margin compression and rapid market share loss to Starlink.

Track Intel Corporation (INTC) as a multi-year turnaround play, as it allocates $2 billion per quarter alongside a fresh $20 billion capital raise to establish itself as the premier Western semiconductor foundry alternative to Taiwan Semiconductor Manufacturing Company (TSMC).

Prepare for a potential near-term public listing from private AI developer Anthropic, which has updated its enterprise security terms ahead of an anticipated initial public offering (IPO) in the coming weeks while navigating pricing pressure from low-cost open-weight AI models.

Moderna (MRNA) and Merck (MRK) offer compelling upside in the multi-billion-dollar oncology market following breakthrough Phase 3 clinical trial results that cut melanoma recurrence by 49% using personalized mRNA vaccines.

Severe high-bandwidth memory shortages make semiconductor memory leaders like SK Hynix (HXSCF) prime investment targets, with cloud providers locking in supply contracts that provide clear pricing power through 2027.

Uber Technologies (UBER) presents an actionable play on automated logistics, utilizing an asset-light aggregation model alongside Zipline to target over one million daily low-cost autonomous drone deliveries.

Watch for major liquidity events in Frontier AI, as Anthropic explores a record-setting Initial Public Offering (IPO) valued at up to $2 trillion with high probabilities of a year-end listing.

Longer-term hardware investors should begin diversifying beyond general GPUs into specialized ASIC chipmakers and silicon etching technology, which provide up to 1,000x computational efficiency gains for standardized AI workloads.

Exercise caution with overvalued U.S. Big Tech software providers and prepare for potential market corrections over a 2- to 3-year horizon as low-cost open-source models erode high-margin pricing power. Keep a close watch on NVIDIA (NVDA), as aggressive debt-financed data center spending and emerging Chinese competition could lead to cyclical demand pullbacks in the coming years. Maintain exposure to Taiwan Semiconductor Manufacturing Company (TSM) as the critical global compute backbone, while tracking the progress of subsidized overseas factory expansions to offset geopolitical risk. Consider investment exposure to Alibaba Group Holding Limited (BABA) and the broader Chinese open-source AI ecosystem, which are rapidly capturing developer market share through low-cost enterprise adoption. In the robotics sector, avoid speculative humanoid startups facing heavy industry consolidation over the next 12 to 24 months, focusing capital instead on practical industrial automation and component suppliers.

Invest in heavy equipment manufacturers like General Electric (GE) to capitalize on massive multi-year backlogs for modular natural gas turbines, which serve as the primary interim power source for AI data centers through the late 2020s.

Allocate to utility-scale solar and battery storage providers such as Tesla (TSLA), which offer the fastest 12-month deployment timeline and lowest cost structure to bypass multi-year electrical grid queues.

Target power grid infrastructure and utility operators through the Utilities Select Sector SPDR Fund (XLU), focusing on grid-orchestration and battery technologies that reduce connection wait times from seven years down to 12 to 18 months.

Focus nuclear investments on conventional nuclear reactor restarts over the next three to five years, rather than early-stage Small Modular Reactors (SMRs) that face commercial delays until the 2030s.

Maintain a cautious view on NVIDIA (NVDA) over the next one to two years, as severe physical power bottlenecks and emerging compiler tools risk eroding its hardware pricing power and software moat.

Capitalize on NVIDIA (NVDA) as a foundational growth play, driven by a monumental $500 billion partnership with top asset managers to directly fund AI infrastructure. Watch for commercial service launches and regulatory milestones from electric vertical takeoff and landing leaders Joby Aviation (JOBY) and Archer Aviation (ACHR) as they scale toward a $3 per seat mile pricing model. Monitor Joby and Archer for imminent commercial flight operations in key markets like Dubai and the U.S. Keep a close eye on Archer following its recent consolidation wave and strategic equity backing from Boeing (BA). Investors should balance these high-growth opportunities against risks like rapid technological obsolescence for NVDA hardware and execution hurdles in the emerging eVTOL sector.

Investors should capitalize on the explosive growth of artificial intelligence by buying NVIDIA ($NVDA**), which maintains a dominant position as persistent compute demand continues to outpace hardware supply. Treat compute capacity as an emerging, globally traded asset class by monitoring new financial derivatives and futures contracts tied to NVIDIA hardware through emerging marketplace exchanges. Exercise caution with Alphabet ($GOOGL)** shares near-term, as the company faces fierce competition and is skipping model releases while restructuring its frontier AI strategy under Sergey Brin. However, long-term investors can view Alphabet ($GOOGL**)** pullbacks as an opportunity to buy a massive distribution and cloud infrastructure moat at a discount. Watch for upcoming GPU compute futures contracts referencing H100, H200, B200, and RTX 5090 chips to hedge or speculate on enterprise computing costs over the next year.

For accredited investors with private market access, SpaceX represents a generational infrastructure play as it scales toward a projected $100 billion in ARR by year-end.

Investors looking for liquid opportunities should watch Alibaba Group Holding Limited ($BABA**)** closely as its aggressively priced Qwen 3.8 Max model accelerates enterprise AI adoption.

The launch of the TeraFab joint venture by SpaceX and Tesla ($TSLA**)** signals a massive incoming disruption to traditional semiconductor manufacturers like TSMC ($TSM**)** and ASML Holding ($ASML**)** over the next few years.

With Alibaba ($BABA**)** undercutting Western AI competitors by up to 88% on cost, international open-weight models are creating a profitable new wave for cost-conscious enterprise software buyers.

Capitalize on the massive artificial intelligence infrastructure boom by investing in leading semiconductor providers like NVIDIA (NVDA) and AMD.

Ride the booming optical networking supply chain by accumulating shares of Corning (GLW), which is currently fulfilling its largest infrastructure orders in history.

Position your portfolio to benefit from aggressive government import restrictions by targeting domestic U.S. robotics and autonomous drone manufacturers.

Look for high-growth opportunities at the intersection of technology and healthcare by investing in pharmaceutical companies that are leveraging emerging quantum computing for advanced drug discovery.

Finally, monitor private venture capital trends in commercial nuclear fusion and clean energy infrastructure for lucrative long-term growth plays.

Buy NVIDIA (NVDA) as the premier AI hardware play that profits regardless of whether the industry adopts open-source or proprietary models. Accumulate Palantir Technologies (PLTR) to capitalize on enterprise demand for secure, on-premises AI deployment built in partnership with NVIDIA. Monitor regulatory developments ahead of the August 1st federal deadline, as new mandates could solidify the market power of major closed-source incumbents. Invest in semiconductor foundries like TSMC (TSM) to capture essential value as the foundational picks-and-shovels providers of the AI infrastructure stack. Exercise caution with high-valuation proprietary model providers like Anthropic as intensifying competition from open-source alternatives threatens to compress profit margins.

Focus your portfolio on the commercial space sector, prioritizing foundational revenue drivers like launch services, satellite communications, and Earth observation over speculative long-term bets.

Target well-capitalized private space giants partnering with government agencies like NASA, as government-backed infrastructure development accelerates near-term commercial viability.

Capitalize on the breakthrough trend of rapid rocket reusability, which is actively lowering the cost of mass transport to orbit and unlocking new multi-billion-dollar addressable markets.

Watch for emerging investment opportunities in orbital data centers and space-based infrastructure, which aim to leverage solar energy and advanced computing in low-Earth orbit.

Maintain a balanced risk approach by separating proven near-term commercial space catalysts from long-term, high-risk endeavors like asteroid mining or lunar real estate over the next several years.

Capitalize on the rapid evolution of autonomous AI agents bypassing traditional security controls by investing in leading cybersecurity firms building advanced threat-patching architectures. Monitor regulatory trade actions involving Chinese open-weight models like Kimi K3, recognizing that enforcing bans on widely accessible software remains practically difficult. Position for a paradigm shift in biotech and materials science by tracking AI-native scientific laboratories and agile startups benefiting from the $5 billion expansion of the Genesis mission. Capitalize on the explosive growth of longevity biotechnology by tracking upcoming clinical trial milestones from epigenetic reprogramming pioneers like Life Biosciences. Accumulate positions in enterprise archives and content holders sitting on verified, pre-2022 human-generated data repositories that carry immense economic value for training foundation models.

The release of Moonshot AI’s Kimi K3 marks a "Sputnik moment" for China, signaling that investors should pivot toward companies capable of implementing high-end, open-source models rather than those relying on expensive, closed-source API providers. NVIDIA (NVDA) remains a high-conviction play as the global AI arms race intensifies, driven by the "Jevons Paradox" where increased software efficiency actually explodes the total demand for hardware. Look for opportunities in Edge AI and hardware leaders like Samsung that specialize in "sub-1-bit quantization," which allows powerful AI to run locally on smartphones without an internet connection. Cybersecurity is currently the most critical venture capital category; prioritize firms that integrate automated AI defense to counter the surge in unregulated, open-source AI "superweapons." Finally, favor companies with "proprietary data moats" like JP Morgan or Meta (META) that can use free open-weights to build sovereign internal systems, while remaining cautious of traditional consulting and middle-management heavy industries.

Investors should pivot toward Edge AI by monitoring hardware leaders like Qualcomm (QCOM) and AMD (AMD), as companies like Liquid AI shift intelligence from the cloud to local devices. Watch for Mercedes-Benz (MBGYY) to lead the automotive sector in 2024 by deploying efficient, on-device models that operate without data center reliance. The rise of "Sovereign AI" makes open-weight models a high-conviction play, favoring platforms that allow enterprises to fine-tune AI on-premise to protect proprietary data. Meta (META) remains a dominant force in healthcare disruption, using its free MuseSpark models to demonetize medical diagnostics and create a massive competitive moat. In the biotech space, focus on longevity startups like Revel Pharmaceuticals that are moving beyond symptom management to actively reverse cellular aging through protein repair.